{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:44:25Z","timestamp":1764510265875,"version":"3.40.4"},"reference-count":2,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2004]]},"abstract":"<i>Background:<\/i> t(11;18)(q21;q21) resulting in the <i>API2-MALT1<\/i> fusion transcript is an exclusive finding in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). While it has recently been demonstrated as a negative predictor for gastric MALT lymphoma undergoing eradication of <i>Helicobacter pylori<\/i>, nothing is known about the relation between t(11;18)(q21;q21) status and response to chemotherapy. We have therefore performed a retrospective analysis of t(11;18)(q21;q21) in patients undergoing chemotherapy with the nucleoside analogue cladribine (2CdA) for gastric MALT lymphoma. <i>Patients and Methods:<\/i> Eighteen cases of gastric MALT lymphoma treated with 2CdA were reviewed, and 17 could be investigated for t(11;18)(q21;q21) by reverse-transcription polymerase chain reaction and fluorescence in situ hybridization. t(11;18)(q21;q21) was correlated with response to chemotherapy. <i>Results:<\/i> Of the 17 patients with gastric MALT lymphoma treated with 2CdA, 9 were at stage IE, 2 at stage IIE and 6 at stage IV. Eight cases with stage IE lymphoma were first treated with <i>H. pylori<\/i> eradication, but none of them showed histological regression during a minimum follow-up of 12 months, and they were subsequently treated with primary chemotherapy. One patient received chemotherapy due to absence of <i>H. pylori<\/i> infection. Another patient initially rated as stage IE whose gastric lymphoma did not respond developed spread to the lung during follow-up after eradication. All the remaining 13 cases were treated by chemotherapy at the time of diagnosis. Out of these 17, 8 patients (47%) were found to carry t(11;18)(q21;q21). One patient, who was negative for t(11;18)(q21;q21), progressed during chemotherapy and died 5 months after initiation of treatment. One patient each with and without t(11;18)(q21; q21) had a partial response lasting for 14 and >18 months, respectively. One t(11;18)(q21;q21)-positive patient had stable disease for >16 months. The remaining patients achieved a complete remission (CR) following treatment; 6 were positive for t(11;18)(q21;q21), while the remaining 6 were negative. Two patients [1 positive and 1 negative for t(11;18)(q21;q21), respectively] have developed a local relapse following CR and were salvaged by radiotherapy. <i>Conclusion:<\/i> Our findings suggest that the presence of the <i>API2-MALT1<\/i> fusion transcript resulting from t(11;18)(q21;q21) does not adversely affect the response of gastric MALT lymphoma to chemotherapy with 2CdA. 2CdA appears to be an attractive agent for treatment of gastric MALT lymphoma unresponsive to <i>H. pylori<\/i> eradication, including those positive for t(11;18)(q21;q21).<\/jats:p>","DOI":"10.1159\/000079502","type":"journal-article","created":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T09:22:27Z","timestamp":1096017747000},"page":"476-480","source":"Crossref","is-referenced-by-count":41,"title":["Translocation t(11;18)(q21;q21) Is Not Predictive of Response to Chemotherapy with 2CdA in Patients with Gastric MALT Lymphoma"],"prefix":"10.1159","volume":"66","author":[{"given":"Berthold","family":"Streubel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Qing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Chott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,9,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009984200"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.117"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/79502","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/79502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:24:44Z","timestamp":1745465084000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000079502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":2,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000079502","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2004]]}}}